Ruconest FDA Approval History
FDA Approved: Yes (First approved July 16, 2014)
Brand name: Ruconest
Generic name: C1 esterase inhibitor (recombinant)
Previous Name: Rhucin
Company: Pharming Group NV
Treatment for: Hereditary Angioedema
Ruconest is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).
Development Timeline for Ruconest
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.